NDAORALTABLETPriority Review
Approved
Jun 1964
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
4/8 — Partial
Priority Review
AMICAR (aminocaproic acid) by Hikma. Approved for antifibrinolytic agent [epc]. First approved in 1964.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMICAR (aminocaproic acid) is an antifibrinolytic agent that inhibits plasminogen activators and reduces fibrinolysis. It is indicated for anemia and is administered orally as a tablet. The drug works by suppressing the breakdown of blood clots, helping to control hemorrhage in select patient populations.
$60KPart D
LOE ApproachingDeclining
less than 1% of antifibrinolytic market
Product is in late-stage maturity with low commercial demand; expect minimal team expansion and focus on cost management.
Mechanism of Action
Pharmacologic Class:
Antifibrinolytic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AMICAR offers limited career advancement opportunities as a legacy, low-volume product with approaching loss of exclusivity (though already generic). Roles focus on cost management, regulatory compliance, and supply chain efficiency rather than commercial growth or innovation. Career trajectories on this product tend to be lateral or transitional to higher-growth assets within a portfolio.
Product Manager (legacy/SKU management)
Worked on AMICAR at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.